企業プロフィール
Immutep Limited 株価・ニュース・カタリスト
- ティッカー:
- IMMP
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Australia and listed in the U
株価パフォーマンス
0.39 USD (+1.71%)
終値
最終更新: 2026年8月17日
61.3M USD
時価総額
株価変動の要因
As of Aug 17, 2026, IMMP closed up 1.71% at $0.3865. No new same-company headline was identified in the current news window.
企業概要
事業概要
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
所在地とセクター分類
Immutep is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
ビジネスモデルの特徴
The company depends on clinical readouts, translational validation, and the ability to maintain a narrow immunotherapy pipeline. Investors usually watch efficacy signals and strategic collaborations.
バイオ業界での位置付け
Immutep occupies a specialized immuno-oncology niche within biotech. The stock is catalyst-sensitive because the platform still needs to prove broad clinical relevance.
今後のカタリスト
- Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。